EA Pharma Co., Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Ensho Therapeutics Inc. launched on 27 June to announce that it will start Phase II clinical trials in ulcerative colitis (UC) during the first half of 2025 for lead drug candidate NSHO-101 (EA1080),

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorizations for a large group of new drugs that included several world-first clearances for therapies in ulcerative colit